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cancer
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Summary A seasonal variation in the month of initial detection of breast cancer has been previously
observed in pre-menopausal women, and it has been proposed that this may be due to cyclic changes in
tumour growth mediated by the effects of melatonin on ovarian function. To investigate this possibility serum
melatonin concentrations have been measured every 2 h for 24 h at the summer and winter solstice in 20
pre-menopausal women with previous breast cancer and nine controls. Twelve women had detected their
tumour in winter and eight in summer. Overall melatonin secretion assessed by either amplitude of the
noctural melatonin pulse or the area under the 24 h melatonin curve (AUC) was not different between breast
cancer women or controls. However, the amplitude and AUC fell in winter in breast cancer patients (summer
to winter 93.6 to 77.5 pgml1, P<0.002 and 743 to 634 AUC units, P<0.005 for amplitude and AUC
respectively), whereas the winter minus summer values were significantly positive in controls compared with
cancer patients. The abnormal fall in winter values in the women with previous breast cancer was confined to
the group of women who had been winter detectors (mean summer to winter levels 94.9 to 72.6 pgml -,
P<0.01 and 775 to 637 AUC units, P<0.05 for amplitude and AUC respectively) whereas there was no
significant seasonal alteration in these measurements in summer detectors. The acrophase of the noctural pulse
of serum melatonin was significantly advanced in both groups of women with previous breast cancer (change
in acrophase winter to summer from 0210h to 0140h in summer detectors, P<0.01, 0330h to 0210h in
winter detectors, P<0.05) with a similar although nonsignificant trend in control women.
The abnormal reduction of serum melatonin seen in wintertime in winter detectors of breast cancer could
promote tumour growth at this season and so contribute to the decreased survival previously observed in this
group compared with summer detectors. The relatively normal seasonal profile of melatonin observed in
summer detectors could allow increased ovarian steroidogenesis in spring/summer with a resulting increase in
tumour growth and consequent rise in tumour detection rate at this time.
Oestrogen appears to play a major role in the growth of
human breast cancer. Ovarian oestrogen production in
seasonally breeding mammals is regulated in part by the
pineal hormone melatonin (Arendt, 1988), and there is
evidence for seasonal variation in melatonin secretion and
ovarian steroidogenesis in humans (Kauppila et al., 1987).
Serum melatonin levels in women with breast cancer appear
to differ from controls (Blask, 1984; Lissoni et al., 1987) and
these changes are particularly apparent in relation to tumour
stage (Bartsch et al., 1989) and steroid hormone receptor
status (Tamarkin et al., 1982). It is uncertain whether such
changes in serum melatonin have any influence on the
growth of human breast cancer either directly or indirectly
through ovarian oestrogen synthesis. However, the growth of
experimental rat mammary tumours in vivo can be altered by
changes in serum melatonin (Tamarkin et al., 1981), and
there is some evidence for an inhibitory effect of melatonin
on tumour cell growth in vitro (Hill & Blask, 1988).
Several groups have reported a seasonal variation in the
month of initial detection of breast cancer, with maximum
detection in spring-early summer (Lee, 1967; Cohen et al.,
1983; Hartveit et al., 1983; Mason et al., 1985; Kirkham et
al., 1985; Chelboun & Gray, 1987). This pattern of tumour
detection is most apparent in premenopausal women with
receptor positive tumours, leading to speculation that a
hormonally-mediated surge in tumour growth rate in spring
may underlie the observed cyclic variation (Mason et al.,
1985). Seasonal changes in melatonin levels could be one
possible source of such hormonal variation. The present
study has thus been undertaken to determine whether 24h
serum melatonin profiles differ between women who have
been summer or winter detectors of breast cancer, since
differences in melatonin levels between these groups could
provide an explanation for seasonal changes in tumour
growth rate and detection.
Methods
Patients
Nine control women and 20 women with previous breast
cancer provided informed consent for the study. The women
with previous breast cancer were grouped according to
season of initial detection of their original tumour. 'Summer'
detectors found their tumours in October-January (spring/
early summer in New Zealand) and 'winter' detectors
comprised those who detected their tumours during the
remainder of the year. This subdivision provides the clearest
distinction in seasonal tumour detection rates in New Zea-
land (Mason et al., 1985) and has been found to significantly
subdivide breast cancer patients according to risk of tumour
recurrence (Mason et al., 1987), overall survival (Mason et
al., 1990a) and stratification of tumour risk factors (Mason et
al., 1990b). Patient details are shown in Table I. The women
with previous breast cancer were free of recurrence as far as
could be determined. All women were still menstruating
apart from four who had had hysterectomies. In these
women serum oestradiol and gonadotrophin concentrations
were within the premenopausal range. The mean age of the
control women was significantly younger than the subgroup
of 'summer' detectors (Table I) but was not significantly
different from 'winter' detectors, nor were the mean ages of
the winter and summer detector group significantly different.
There was no significant difference in body weight between
groups.
Melatonin profiles
Blood samples were obtained from the subjects every 2 h for
24 h in summer (within 4 weeks of the summer solstice) and
winter (within 4 weeks of the winter solstice). Samples were
withdrawn from an indwelling heparinised venous line. In
seven women difficulties with venous access led to perform-
ance of 4-hourly sampling on one of the experimental days
during the overnight sampling period. The acrophase of
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Table I Patient data
Breast cancer
Winter Summer
Controls detectors detectors
n
Age (yrs) (mean± s.d.)
Time since surgery (yrs) (mean s.d.)
Menstrual status
Regular menses
Hysterectomy
Oral contraceptive
Depot medroxyprogesterone
acetate
Nodal status
Negative
Positive
Unknown
Tumour gradeb
1
2
3
Unknown
Adjuvant therapy
Chemotherapy
Endocrine therapy
Oestrogen receptor status
+
Unknown
Progesterone receptor status
+
Unknown
ap<0.05 compared with controls;
tological grade.
9 12
36.3±6.8 40.5±6.2
- 33±2.6
8
1
0
9
2
0
1
7
3
0
3
2
_ 7
2
0
4
7
3
_ 2
_ 7
8
44.3± 5.1a
3.3 ± 3
7
1 0
0
6
2
1
2
1
4
2
1
5
2
0
6
bBloom and Richardson his-
melatonin release (see below) could not be accurately esti-
mated on these occasions and data from these patients are
excluded from the acrophase assessment. Identical mealtimes
and lighting were employed on the two occasions, with lights
out at 2300 h and lights on at 0730 h.
Assay techniques
Melatonin was measured by radioimmunoassay on unextract-
ed blood using an antiserum (g/s/704-6483) purchased from
Dr J. Arendt (Fraser et al., 1983). The sensitivity of the assay
was 15 picogram per ml. The within assay coefficient of
variation for midrange samples was ± 3.1% and the between
assay coefficient of variation was ± 7.8%.
Statistics
Melatonin secretion over 24 h in individual subjects was
assessed by calculating the area under the concentra-
tion x time curve (AUC), the amplitude of the nocturnal
melatonin pulse, and the acrophase estimated from the best
fit parabola for the 8 pm to 8 am melatonin data. When
E
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E
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Figure 1 Serum melatonin concentrations in controls (9) and
women with previous breast cancer (20) measured at summer
solstice.
calculating the melatonin acrophase 1 h of summer daylight
saving was subtracted from the summer values so that timing
for all samples was referred to the same point on the 24 h
clock (Bojkowski & Arendt, 1988). Summer-to-winter differ-
ences for individual subjects were assessed between groups by
paired t-test, and non paired difference between groups were
tested by analysis of variance.
Results
All patients had low serum melatonin levels during daylight
hours and typical increases in serum melatonin concentration
at night. There was no significant difference in melatonin
levels between women with previous cancer compared with
controls when measured in either summer (Figure 1; Table
II) or winter (Figure 2; Table II) when assessed by either
AUC, amplitude or acrophase of melatonin release. Simi-
larly, within the group of women with previous breast cancer
melatonin levels were not significantly different between sum-
mer and winter detectors (Table II).
Melatonin production in individual subjects in winter is
compared with measurements in summer in Figures 3-5 and
summarised in Table II. Women with previous breast cancer
had significantly greater melatonin secretion, calculated from
the AUC, in summer than in winter (P<0.01), whereas there
was no significant difference in AUC in summer compared to
winter in controls (Table II). Winter detectors of breast
cancer showed significantly (P<0.05) greater AUC values in
summer compared with winter (Figure 3), but there was no
significant summer to winter difference in summer detectors
of breast cancer. The significant AUC differences were due
entirely to differences in the nocturnal levels of melatonin;
subanalysis of AUC values for daytime melatonin concentra-
tions showed no significant differences (data not shown).
There was also a significantly (P<0.01) greater mean
amplitude of the nocturnal melatonin peak in summer com-
Table II Comparison between summer and winter 24 h melatonin profiles in different subgroups
Control Breast cancer
All subjects Summer detectors Winter detectors
Parameter Summer Winter Summer Winter Summer Winter Summer Winter
Measured Mean 80.9 90.4 93.6 77.5 90.3 81.7 94.9 72.6
amplitude n 9 15 8 7
(pg ml-) pa 0.37 0.0015 0.09 0.008
Area under Mean 590 641 743 634 715 631 775 637
the curve n 9 15 8 7
(pgml-' 24h-') P 0.53 0.004 0.07 0.04
Estimated Mean 0205 0155 0250 0.125 0205 0205 0320
acrophase n 9 13 6 7
(time of day, h) P 0.51 0.002 0.004 0.04
ap value for difference between summer and winter measurements.
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Figure 2 Serum melatonin concentrations in controls (9) and
women with previous breast cancer (15) measured at winter
solstice.
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Figure 5 The acrophase of the noctural peak of serum mela-
tonin. (9) = controls, (6) = summer detectors, (7) = winter detec-
tors.
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-80 - Figure 3 The area under the 24 h serum melatonin curve in
summer compared to winter. (9) = controls, (8) = summer detec-
tors, (7) = winter detectors.
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Figure 6 The amplitude of the nocturnal peak of serum mela-
tonin in winter minus the amplitude in summer in controls (9),
summer detectors (8), winter detectors (7).
Breast can
Figure 4 The amplitude of the nocturnal peak of se
tonin in summer compared to winter. (9) = controls,
mer detectors, (7) = winter detectors.
pared with winter in women with previous breast cancer,
although this was not observed in controls (Table II). As
with the AUC data this difference was significant (P<0.01)
in winter detectors of breast cancer, but did not reach statis-
tical significance in summer detectors (Table II; Figure 4).
The calculated acrophase of the noctural melatonin peak
was significantly earlier (P<0.01) in summer compared with
winter in women with previous breast cancer but was not
a significantly different between summer and winter in controls
(Table II; Figure 5). This difference was particularly evident
in summer detectors of breast cancer (P<0.01) and was also
p= 0.008 seen in winter detectors (P<0.05).
The seasonal difference in melatonin levels between groups
s w was also compared by calculating the difference between
Winter winter and summer values for individual patients, and com-
detectors paring groups by analysis of variance (Figures 6 and 7).
icer Using this comparison the winter-to-summer difference in
-rum mela- amplitude was significantly more positive (i.e. winter higher
Xrum mela- than summer) in controls than in patients with previous
(8) = sum- breast cancer (P = 0.01) and between controls, summer detec-
tors and winter dectors (P<0.05) (Figure 6). The winter-to-
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Figure 7 The area under the 24 h serum melatonin curve in
winter minus the area under the curve in summer in controls (9),
summer detectors (8), winter detectors (7).
summer difference in AUC values was also greater (P<0.05)
in controls than in breast cancer patients, but was not
significantly different between summer and winter detectors
of breast cancer (Figure 7). There were no significant differ-
ences in winter-to-summer values for acrophase estimations.
The subdivision of the year into 'summer" (October-
January) and 'winter' (February-September) was based on
the previous observation that October-January were the
months of peak tumour detection (Mason et al., 1985) and
the finding that this seasonal subdivision stratified subjects
according to risk of tumour recurrence (Mason et al., 1987)
patient survival (Mason et al., 1990a) and risk factors for
breast cancer (Mason et al., 1990b). To ensure that the
present findings were not an artefact of this choice of
seasonal division individuals were grouped according to the 3
months centred around the solstices (November-January,
n = 5 and May-July, n = 7). When the serum melatonin
profiles from these groupings were compared the differences
noted in Table II were maintained at the P<0.05 signi-
ficance level, except that the summer to winter differences in
AUC and acrophase in winter detectors of breast cancer were
no longer statistically significant although the mean levels
were closely similar to the earlier analysis.
Discussion
This study shows that there are seasonal differences in
melatonin production in women with previous breast cancer,
whereas such seasonal differences are less apparent in con-
trols. Within the group with previous breast cancer, summer
measurements of melatonin amplitude and AUC were greater
than winter in women who had been winter detectors of
breast cancer. Similar trends were seen in summer detectors,
but the changes were not statistically significant. There was a
significant phase shift in the nocturnal melatonin pulse in
women with previous breast cancer, with the acrophase in
summer being approximately 1 h earlier than in winter. By
comparison with the data for amplitude and AUC, this phase
advance was particularly marked in summer detectors of
breast cancer although a significant difference was also pre-
sent in winter detectors and is similar to seasonal changes in
acrophase noted in normal women (Broadway et al., 1987).
Other researchers have noted differences in total melatonin
secretion between women with breast cancer and controls
(Bartsch et al., 1981, 1989). These studies differ, however,
from the present report in several respects. Bartsch et al.
(1989) studied women with active clinical breast cancer and
found significant melatonin changes only in women with
primary breast tumours. Other workers have also investi-
gated women with overt (usually metastatic) disease (Lissoni
et al., 1987). In the present study it is uncertain how many
women may have had early metastatic disease at the time of
study (30% had been node positive at initial surgery), but all
were free of clinically apparent breast cancer. The design of
this study thus does not address the issue of whether clinic-
ally evident breast cancer may alter melatonin levels. How-
ever, using analysis of variance to compare control women
with those with previous cancer it does appear that the
amplitude of the nocturnal melatonin pulse and the AUC
tends to increase from summer to winter in controls whereas
it falls significantly in women with a previous history of
breast cancer. Whether this has any relevance to the previous
development of breast cancer in these women is uncertain.
Because a large number of comparisons were carried out
the statistical limitations of the present study should be
recognised. It may be more appropriate to limit discussion to
data where the significance of between - group comparisons
is P<0.01. However even with this restriction most of the
differences noted in this study remain significant. It is also
important to recognise that the limited number of individuals
studied reduces the statistical power of the observations, such
that type two errors could readily occur. The larger number
of women with previous breast cancer compared with con-
trols could also explain why some seasonal differences were
seen in the cancer group but not the controls (Table II).
However, the differences in the cancer group were also pre-
sent in subgroups of different seasonal detection where
numbers were similar to the control group. Additionally,
when considering calculation of the melatonin acrophase it is
uncertain whether allowance should be made for daylight
saving such as carried out in this study (see Methods). How-
ever, others have calculated their data in similar fashion
(Bojkowski & Arendt, 1988). It should also be noted that the
control women tended to be younger then the women with
previous breast cancer, and since 24h melatonin secretion
tends to fall with age (Waldhauser et al., 1988) this may have
contributed to the changes seen in Figures 6 and 7. There
was, however, no significant correlation between melatonin
levels and age in the study group (data not shown). It is also
unlikely that age would influence summer-to-winter
differences in 24 h melatonin production. Subject weight,
which may also influence melatonin secretion, appeared
similar in the various groups. By the nature of the study
design it was not possible to control for phase of the mens-
trual cycle at the time of sampling, and although differences
in melatonin during the cycle are small (Webley &
Leidenberger, 1986) differences in time of cycle between sum-
mer and. winter sampling may have influenced the present
results. It was, however, considered important to study
premenopausal women since this is the group showing
greatest seasonal variability in tumour detection (Mason et
al., 1985).
Despite these reservations the present results appear con-
sistent and indicate that premenopausal women with previous
breast cancer have a significant summer to winter reduction
in melatonin secretion assessed by both melatonin pulse amp-
litude and AUC. These changes were particularly apparent in
winter detectors of breast cancer (Figures 3 and 4), but were
inconsistently related to receptor status. However, there were
too few subjects with receptor data to draw firm conclusions
about seasonal melatonin changes and receptor levels. By
contrast, normal women tested at extremes of latitude pro-
duce more melatonin in winter than summer (Kauppila et al.,
1987), and a similar trend was noted in the control women in
this study (Figures 6 and 7). There was also a significant
phase advance of the noctural melatonin pulse in summer in
women with previous breast cancer, more marked in summer
detectors, but this is similar to the pattern previously
reported in normal individuals (Broadway et al., 1987). The
failure to observe such a change in control subjects in the
present study may in part relate to the lower numbers stud-
ied, and may also have been influenced by the enforced
a)
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V
2
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similarity of light/dark cycling on the summer and winter
experimental days.
The pathophysiological significance of these seasonal
abnormalities in melatonin secretion remains uncertain. It is
possible that the previous breast cancer may have altered the
seasonality of melatonin production in the study women.
However, in other reports an abnormal pattern of melatonin
secretion in women with primary breast cancer was no longer
observed in women at a later stage of disease (Bartsch et al.,
1989), so a carry over effect of the previous tumour in this
study is unlikely. The women with previous breast cancer
appeared to have a phase advance of noctural melatonin
secretion in summer similar to that described in normal
women (Broadway et al., 1987) and similar to the trends seen
in control women (Figure 5). However, they also demon-
strated an abnormal fall in melatonin levels in winter
(Figures 3 and 4) compared with the usual rise in melatonin
in winter seen in normal women (Kauppila et al., 1987). This
abnormality appeared to be restricted to those who were
winter detectors ofbreast cancer. In view ofthe evidence that
melatonin may suppress tumour growth (Blask, 1984) this
seasonal abnormality could permit tumour progression over
the wintertime and so contribute to the comparatively poorer
prognosis of winter detectors of breast cancer (Mason et al.,
1990). By contrast, there seemed to be no major alterations
in melatonin levels in summer detectors of breast cancer
compared with control women. In these individuals the nor-
mal reduction in melatonin secretion in spring may permit an
increase of ovarian steroidogenesis (Kauppila et al., 1987)
and/or pituitary production of prolactin (Wright et al., 1986)
and so lead to a surge in tumour growth and subsequent
tumour detection at this time. This would be particularly
likely to occur in those with hormone-responsive tumours
(Mason et al., 1985).
If intrinsic melatonin rhythms are important in the biology
of breast cancer it may be possible to utilise this information
clinically. Knowledge of melatonin rhythms, for example
from single point nocturnal sampling or urinary melatonin
levels (Bojkowski et al., 1987) may help predict those women
at increased risk of breast cancer. Information concerning
seasonal changes in tumour detection should also help in
design of programmes for breast screening and early tumour
detection. Finally, restoration of disordered melatonin
rhythms to normal, for example with exogenous melatonin,
may help reduce the risk ofdeveloping breast cancer or assist
in treatment of established disease.
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